::ODMA\MHODMA\iManage;260809;1 HEW/RHU November 12, 2001



PATENT APPLICATION Attorney's Docket No.:1855.1017-000 (LKS95-10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman,

Jose Saldanha and Mary M. Bendig

Application No.:

08/700,737

Group:

1644

Filed:

August 15, 1996

Examiner:

P. Gambel

For:

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH $\alpha 4\beta 7$ INTEGRIN

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on 11.12.01 Date Signature Daniele D. Gath Typed or printed name of person signing certificate	
	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on 11.12.01 Date Signature Danielle D. Gath

STATEMENT UNDER 37 C.F.R. § 1.806 AND § 1.808

Box Missing Parts Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.806 and § 1.808 the undersigned states:

The above-referenced application contains reference to a biological deposit.
 Murine Act-1 Hybridoma cell line, which produces the murine Act-1 monoclonal antibody that binds human α4β7, was deposited under the provisions of the Budapest Treaty on August 22, 2001, on behalf Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, U.S.A., at the American Type Culture

Collection, 10801 University Boulevard, Manassas, Virginia 20110, U.S.A., under Accession No. PTA-3663.

- 2. Deposit PTA-3663 will be maintained in a public depository for the enforceable life of the patent which issues from the above-referenced application, a term of at least thirty years from the date of deposit or at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, whichever is longer.
- 3. In accordance with 37 C.F.R. §1.808(a)(1), access to deposit PTA-3663 will be available during the pendency of the above-referenced application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122.
- 4. In accordance with 37 C.F.R. §1.808(a)(2), and except as permitted by 37 C.F.R. §1.808(b), all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent on the above-referenced application.
- 5. The undersigned is an agent of record.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Robert H. Underwood

Registration No. 45,170

Telephone (978) 341-0036

Facsimile (978) 341-0136

::ODMA\MHODMA\iManage;268879;1 HEW/RHU November 7, 2001



PATENT APPLICATION Attorney's Docket No.: 1855.1017-000 (LKS95-10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman,

Jose Saldanha and Mary M. Bendig

Application No.:

08/700,737

Group:

1644

Filed:

August 15, 1996

Examiner:

P. Gambel

For:

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH $\alpha 4\beta 7$ INTEGRIN

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the		
United States Postal Service with sufficient postage as First Class Mail in		
an envelope addressed to Assistant Commissioner for Patents,		
Washington, D.C. 20231		
on 11.12.01	Danuivotte	
Date	Signature	
Danielle D. Gath		
Typed or printed name of person signing certificate		

STATEMENT UNDER 37 C.F.R. § 1.804(b)

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

I, Walter Newman, Ph.D., of 3 Durham Street, Apartment 3, Boston, Massachusetts 02115, hereby state that:

- 1. I am a co-inventor of the above-referenced patent application, and I am familiar with the application and the invention claimed therein.
- 2. The above-referenced application, as amended, contains reference to a biological deposit. Murine ACT-1 Hybridoma cell line, which produces murine ACT-1 monoclonal antibody that binds human α4β7, was deposited under the provisions of the Budapest Treaty on August 22, 2001, on behalf Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, U.S.A., at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., under Accession No. PTA-3663.
- 3. The hybridoma cell line deposited at the American Type Culture Colection under Accession No. PTA-3663 is a biological material specifically identified in the subject application as filed.

Walter Newman, Ph.D.

Date